Delivery Order SPE2DR25D2003-SPE2DR26FQ98Q
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,732.10 to AmerisourceBergen Drug Corp for the supply of Terbinafine HCL 250 mg tablets (30-count) with an ultimate completion date of November 17, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,706.98 to AmerisourceBergen Drug Corp for the supply of Terbinafine HCL 250 mg tablets (30-count units). The contract was awarded on December 3, 2025, with an ultimate completion date of December 4, 2025, under a firm fixed-price arrangement with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $3,496.06 to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Terbinafine HCL 250 mg tablets (30-count packages). This firm fixed-price delivery order, with a completion date of November 25, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The contract reflects routine federal medical procurement activities supporting...
- The Defense Logistics Agency awarded a delivery order valued at $1,994.33 to AmerisourceBergen Drug Corp for Terbinafine HCL 250 mg tablets (90-count) on August 22, 2025, with a completion date of August 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply delivery under the Defense Logistics Agency's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,695.88 to AmerisourceBergen Drug Corp for the supply of Terbinafine HCL 250 mg tablets (30-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded and due for completion by November 18, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Terbinafine HCL 250 mg tablets (30-count) on September 15, 2025, with a ceiling value of $42,385.52. This firm fixed-price delivery order, which is expected to be completed by September 16, 2025, represents a routine pharmaceutical procurement supporting federal medical supply needs. The contract was competitively awarded without set-aside provisions, demonstrating AmerisourceBergen's capability to...
- The Defense Logistics Agency awarded a delivery order valued at $5,773.71 to AmerisourceBergen Drug Corp for the supply of Terbinafine HCL 250 mg tablets (90-count) with a completion date of December 3, 2025. This competitive award utilizes firm fixed pricing and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement serving military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $1,163.04 to AmerisourceBergen Drug Corp for Terbinafine HCL 250 mg tablets (90-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Terbinafine HCL 250 mg tablets in quantities of 30 units, with a ceiling value of $3,320.50. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a typical transactional delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a firm fixed-price delivery order valued at $1,045.22 for the supply of Terbinafine HCL 250 mg tablets (30-count units). The contract, awarded on December 3, 2025, with a completion date of December 4, 2025, represents a non-competitive delivery order issued under a larger indefinite delivery vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office...
- SPE2DR25D2003Indefinite Delivery Contract
- SPE2DR25D2003-SPE2DR26FQ98QDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,784.72 to AmerisourceBergen Drug Corp for the supply of Terbinafine HCL 250 mg tablets (90-count) on November 24, 2025, with an ultimate completion date of November 25, 2025. This is a firm fixed price, non-set-aside contract with performance conducted at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999.99 million and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal vendor for military and veteran healthcare systems. The company has demonstrated its capability to fulfill federal procurement requirements through open competition, as evidenced by its extensive portfolio of competitively awarded delivery orders covering a broad spectrum of pharmaceutical products including brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This particular delivery order represents a routine pharmaceutical supply transaction supporting the DLA's medical supply chain operations for federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 11/23/25 |